We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+44.88%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$346M
AUM Growth
–
Cap. Flow
+$310M
Cap. Flow %
89.56%
Top 10 Hldgs %
37.82%
Holding
69
New
69
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$18.9M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$16.3M
3
ZBH icon
Zimmer Biomet
ZBH
+$13.5M
4
SGEN
Seagen Inc. Common Stock
SGEN
+$12.7M
5
BSX icon
Boston Scientific
BSX
+$11.5M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 91.87%
2 Industrials 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRK icon
1
Merck
MRK
$317B
$20M 5.78%
+230,560
New +$18.9M
NBIX icon
2
Neurocrine Biosciences
NBIX
$16.2B
$16.7M 4.82%
+155,425
New +$16.3M
ZBH icon
3
Zimmer Biomet
ZBH
$18.8B
$14.2M 4.11%
+97,850
New +$13.5M
SGEN
4
DELISTED
Seagen Inc. Common Stock
SGEN
$13.7M 3.97%
+120,221
New +$12.7M
KOD icon
5
Kodiak Sciences
KOD
$2.84B
$12.6M 3.63%
+174,538
New +$6.35M
BSX icon
6
Boston Scientific
BSX
$71.4B
$12.4M 3.59%
+275,000
New +$11.5M
EIDX
7
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$11.9M 3.43%
+207,271
New +$10.3M
GWPH
8
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$9.93M 2.87%
+95,000
New +$10.7M
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$123B
$9.89M 2.86%
+45,176
New +$9.14M
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$9.62M 2.78%
+265,840
New +$8.15M
KPTI icon
11
Karyopharm Therapeutics
KPTI
$44.2M
$9.59M 2.77%
+33,333
New +$7.23M
ISRG icon
12
Intuitive Surgical
ISRG
$132B
$9.16M 2.65%
+46,500
New +$8.71M
VCEL icon
13
Vericel Corp
VCEL
$2.29B
$8.33M 2.4%
+478,500
New +$8.15M
TNDM icon
14
Tandem Diabetes Care
TNDM
$1.29B
$8.04M 2.32%
+134,959
New +$8.32M
SILK
15
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
$7.87M 2.27%
+195,000
New +$6.83M
XENE icon
16
Xenon Pharmaceuticals
XENE
$6.24B
$7.71M 2.23%
+588,059
New +$6.19M
DXCM icon
17
DexCom
DXCM
$31.3B
$7.66M 2.21%
+140,000
New +$6.64M
UNH icon
18
UnitedHealth
UNH
$367B
$7.35M 2.12%
+25,000
New +$6.54M
XBI icon
19
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.1B
$7.13M 2.06%
+75,000
New +$6.49M
TFX icon
20
Teleflex
TFX
$6.15B
$7M 2.02%
+18,600
New +$6.4M
HAE icon
21
Haemonetics
HAE
$3.86B
$6.92M 2%
+60,250
New +$7.29M
PTLA
22
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$6.58M 1.9%
+275,505
New +$7.6M
IQV icon
23
IQVIA
IQV
$38.3B
$6.37M 1.84%
+41,250
New +$6.02M
TPTX
24
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$6.32M 1.82%
+101,434
New +$4.83M
DRNA
25
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$5.29M 1.53%
+240,000
New +$4.83M
1
2 3

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
SFO
Stokes Family Office New Orleans, Louisiana $969M AUM 19.6% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
PWPS
Pinnacle Wealth Planning Services Mansfield, Ohio $968M AUM 19.1% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return

Parkman Healthcare Partners's Q4 2019 Portfolio in Review

Q4 2019 is the first quarter with a 13F filing on record for Parkman Healthcare Partners, which disclosed 69 positions worth $346M. Its ten largest holdings account for 38% of the portfolio.

Its largest position is Merck: 230,560 shares worth $20M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, followed by Industrials.

  • Parkman Healthcare Partners's largest Q4 2019 buy was Merck: 230,560 shares worth $20M.
  • Parkman Healthcare Partners's ten largest holdings make up 38% of its $346M portfolio in Q4 2019.
  • Parkman Healthcare Partners disclosed 69 positions in Q4 2019, its first 13F filing on record.

Based on Parkman Healthcare Partners's 13F filing for Q4 2019, filed 13 Feb 2020.